Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 7,609 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cidara Therapeutics Inc | CDTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0001 | -0.01% | 0.7219 | 08:43:47 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.722 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 19 | 7,609 | - | 0.593 - 1.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:49:06 | formt | 550 | $ 0.7219 | USD |
Cidara Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 65.11M | 90.43M | - | 64.29M | -29.8M | -0.33 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cidara Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CDTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.8641 | 0.8911 | 0.69 | 0.7558554 | 513,877 | -0.1422 | -16.46% |
| 1 Month | 0.8187 | 1.22 | 0.69 | 0.9497409 | 1,071,262 | -0.0968 | -11.82% |
| 3 Months | 0.676 | 1.22 | 0.625 | 0.8186694 | 713,311 | 0.0459 | 6.79% |
| 6 Months | 0.86 | 1.22 | 0.593 | 0.8011095 | 634,871 | -0.1381 | -16.06% |
| 1 Year | 1.13 | 1.48 | 0.593 | 0.9602964 | 679,925 | -0.4081 | -36.12% |
| 3 Years | 2.10 | 2.39 | 0.40 | 1.24 | 800,204 | -1.38 | -65.62% |
| 5 Years | 2.31 | 4.45 | 0.40 | 1.59 | 633,263 | -1.59 | -68.75% |
Cidara Therapeutics Description
| Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. |
